全文获取类型
收费全文 | 54篇 |
免费 | 5篇 |
专业分类
妇产科学 | 1篇 |
基础医学 | 7篇 |
口腔科学 | 1篇 |
临床医学 | 2篇 |
内科学 | 7篇 |
皮肤病学 | 1篇 |
神经病学 | 2篇 |
外科学 | 2篇 |
综合类 | 1篇 |
药学 | 11篇 |
肿瘤学 | 24篇 |
出版年
2021年 | 2篇 |
2020年 | 1篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 3篇 |
2014年 | 4篇 |
2013年 | 5篇 |
2012年 | 2篇 |
2011年 | 9篇 |
2010年 | 2篇 |
2009年 | 1篇 |
2008年 | 6篇 |
2007年 | 3篇 |
2006年 | 2篇 |
2002年 | 1篇 |
2000年 | 3篇 |
1999年 | 1篇 |
1997年 | 1篇 |
1995年 | 1篇 |
1992年 | 2篇 |
1989年 | 1篇 |
1982年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有59条查询结果,搜索用时 15 毫秒
1.
Cheng M De B Almstead NG Pikul S Dowty ME Dietsch CR Dunaway CM Gu F Hsieh LC Janusz MJ Taiwo YO Natchus MG Hudlicky T Mandel M 《Journal of medicinal chemistry》1999,42(26):5426-5436
The synthesis and structure-activity relationship (SAR) studies of a series of proline-based matrix metalloproteinase inhibitors are described. The data reveal a remarkable potency enhancement in those compounds that contain an sp(2) center at the C-4 carbon of the ring relative to similar, saturated compounds. This effect was noted in compounds that contained a functionalized oxime moiety or an exomethylene at C-4, and the potencies were typically <10 nM for MMP-3 and <100 nM for MMP-1. Comparisons were then made against compounds with similar functionality where the C-4 carbon was reduced to sp(3) hybridization and the effect was typically an order of magnitude loss in potency. A comparison of compounds 14 and 34 exemplifies this observation. An X-ray structure was obtained for a stromelysin-inhibitor complex which provided insights into the SAR and selectivity trends observed within the series. In vitro intestinal permeability data for many compounds was also accumulated. 相似文献
2.
Cust AE Harland M Makalic E Schmidt D Dowty JG Aitken JF Agha-Hamilton C Armstrong BK Barrett JH Chan M Chang YM Gascoyne J Giles GG Holland EA Kefford RF Kukalizch K Lowery J Randerson-Moor JA Schmid H Taylor CF Whitaker L Hopper JL Newton-Bishop JA Mann GJ Bishop DT Jenkins MA 《Journal of medical genetics》2011,48(4):266-272
3.
Aung Ko Win Jeanette C. Reece Daniel D. Buchanan Mark Clendenning Joanne P. Young Sean P. Cleary Hyeja Kim Michelle Cotterchio James G. Dowty Robert J. MacInnis Katherine M. Tucker Ingrid M. Winship Finlay A. Macrae Terrilea Burnett Loïc Le Marchand Graham Casey Robert W. Haile Polly A. Newcomb Stephen N. Thibodeau Noralane M. Lindor John L. Hopper Steven Gallinger Mark A. Jenkins 《Familial cancer》2015,14(4):575-583
4.
5.
Hopper JL Jenkins MA Dowty JG Dite GS Apicella C Keogh L Win AK Young JP Buchanan D Walsh MD Rosty C Baglietto L Severi G Phillips KA Wong EM Dobrovic A Waring P Winship I Ramus SJ Giles GG Southey MC 《Pathology》2012,44(2):89-98
Genes have been identified for which germline mutations are associated with high lifetime risks of breast, colorectal and other cancers. Identification of mutation carriers through genetic testing is important as it could help lower cancer incidence and mortality. The translation of genetic information into better health outcomes is expensive because of the costs of genetic counselling as well as laboratory testing. Approaches to triage for mutation screening of known genes which rely on cancer family history are not necessarily sensitive and specific or the most cost-effective. Recent population-based research has shown that the cancers and precancerous lesions arising in mutation carriers have specific molecular and morphological characteristics. People with colorectal cancer, especially those diagnosed at a young age, whose tumours exhibit microsatellite instability and some specific pathology and immunohistochemically-defined features are more likely to carry a germline mutation in one of four mismatch repair genes. Some morphological and immunohistochemically-defined features are associated with breast cancers arising in women who carry BRCA1 or BRCA2 germline mutations, especially if at a young age. Screening paradigms based on molecular and morphological features that predict mutation status, especially if focused on early-onset disease, have the potential to identify mutation carriers with greater sensitivity and specificity, and in a more cost-effective way, than those based on family history alone. Genetic testing results could help inform treatment if those affected are tested soon after diagnosis using pathology-led selection strategies to identify cases most likely to carry germline mutations. We propose how this new approach could be undertaken by having genetic testing and counselling prioritised to those with the greatest probability of carrying a germline mutation in these known cancer predisposition genes. 相似文献
6.
Tian X Switzer AG Derose SA Mishra RK Solinsky MG Mumin RN Ebetino FH Jayasinghe LR Webster ME Colson AO Crossdoersen D Pinney BB Farmer JA Dowty ME Obringer CM Cruze CA Burklow ML Suchanek PM Dong L Dirr MK Sheldon RJ Wos JA 《Journal of medicinal chemistry》2008,51(19):6055-6066
A study that was designed to identify plausible replacements for highly basic guanidine moiety contained in potent MC4R agonists, as exemplified by 1, led to the discovery of initial nonguanidine lead 5. Propyl analog 23 was subsequently found to be equipotent to 5, whereas analogs bearing smaller and branched alkyl groups at the 3 position of the oxopiperazine template demonstrated reduced binding affinity and agonist potency for MC4R. Acylation of the NH2 group of the 4F-D-Phe residue of 3-propyl analog 23 significantly increased the binding affinity and the functional activity for MC4R. Analogs with neutral and weakly basic capping groups of the D-Phe residue exhibited excellent MC4R selectivity against MC1R whereas those with an amino acid had moderate MC4R/MC1R selectivity. We have also demonstrated that compound 35 showed promising oral bioavailability and a moderate oral half life and induced significant weight loss in a 28-day rat obesity model. 相似文献
7.
Harindra Jayasekara Robert J. MacInnis James A. Chamberlain Gillian S. Dite Nicole M. Leoce James G. Dowty Adrian Bickerstaffe Aung Ko Win Roger L. Milne Graham G. Giles Mary Beth Terry Diana M. Eccles Melissa C. Southey John L. Hopper 《International journal of cancer. Journal international du cancer》2019,145(12):3207-3217
Our aim was to estimate how long-term mortality following breast cancer diagnosis depends on age at diagnosis, tumor estrogen receptor (ER) status, and the time already survived. We used the population-based Australian Breast Cancer Family Study which followed-up 1,196 women enrolled during 1992–1999 when aged <60 years at diagnosis with a first primary invasive breast cancer, over-sampled for younger ages at diagnosis, for whom tumor pathology features and ER status were measured. There were 375 deaths (median follow-up = 15.7; range = 0.8–21.4, years). We estimated the mortality hazard as a function of time since diagnosis using a flexible parametric survival analysis with ER status a time-dependent covariate. For women with ER-negative tumors compared with those with ER-positive tumors, 5-year mortality was initially higher (p < 0.001), similar if they survived to 5 years (p = 0.4), and lower if they survived to 10 years (p = 0.02). The estimated mortality hazard for ER-negative disease peaked at ~3 years post-diagnosis, thereafter declined with time, and at 7 years post-diagnosis became lower than that for ER-positive disease. This pattern was more pronounced for women diagnosed at younger ages. Mortality was also associated with lymph node count (hazard ratio (HR) per 10 nodes = 2.52 [95% CI:2.11–3.01]) and tumor grade (HR per grade = 1.62 [95% CI:1.34–1.96]). The risk of death following a breast cancer diagnosis differs substantially and qualitatively with diagnosis age, ER status and time survived. For women who survive >7 years, those with ER-negative disease will on average live longer, and more so if younger at diagnosis. 相似文献
8.
Win AK Dowty JG English DR Campbell PT Young JP Winship I Macrae FA Lipton L Parry S Young GP Buchanan DD Martínez ME Jacobs ET Ahnen DJ Haile RW Casey G Baron JA Lindor NM Thibodeau SN Newcomb PA Potter JD Le Marchand L Gallinger S Hopper JL Jenkins MA 《British journal of cancer》2011,105(1):162-169
Background:
Carriers of germline mutations in DNA mismatch repair (MMR) genes have a high risk of colorectal cancer (CRC), but the modifiers of this risk are not well established. We estimated an association between body mass index (BMI) in early adulthood and subsequent risk of CRC for carriers and, as a comparison, estimated the association for non-carriers.Methods:
A weighted Cox regression was used to analyse height and weight at 20 years reported by 1324 carriers of MMR gene mutations (500 MLH1, 648 MSH2, 117 MSH6 and 59 PMS2) and 1219 non-carriers from the Colon Cancer Family Registry.Results:
During 122 304 person-years of observation, we observed diagnoses of CRC for 659 carriers (50%) and 36 non-carriers (3%). For carriers, the risk of CRC increased by 30% for each 5 kg m–2 increment in BMI in early adulthood (hazard ratio, HR: 1.30; 95% confidence interval, CI: 1.08–1.58; P=0.01), and increased by 64% for non-carriers (HR: 1.64; 95% CI: 1.02–2.64; P=0.04) after adjusting for sex, country, cigarette smoking and alcohol drinking (and the MMR gene that was mutated in carriers). The difference in HRs for carriers and non-carriers was not statistically significant (P=0.50). For MLH1 and PMS2 (MutLα heterodimer) mutation carriers combined, the corresponding increase was 36% (HR: 1.36; 95% CI: 1.05–1.76; P=0.02). For MSH2 and MSH6 (MutSα heterodimer) mutation carriers combined, the HR was 1.26 (95% CI: 0.96–1.65; P=0.09). There was no significant difference between the HRs for MutLα and MutSα heterodimer carriers (P=0.56).Conclusion:
Body mass index in early adulthood is positively associated with risk of CRC for MMR gene mutation carriers and non-carriers. 相似文献9.
Win AK Cleary SP Dowty JG Baron JA Young JP Buchanan DD Southey MC Burnett T Parfrey PS Green RC Le Marchand L Newcomb PA Haile RW Lindor NM Hopper JL Gallinger S Jenkins MA 《International journal of cancer. Journal international du cancer》2011,129(9):2256-2262
Cancer risks for a person who has inherited a MUTYH mutation from only one parent (monoallelic mutation carrier) are uncertain. Using the Colon Cancer Family Registry and Newfoundland Familial Colon Cancer Registry, we identified 2,179 first- and second-degree relatives of 144 incident colorectal cancer (CRC) cases who were monoallelic or biallelic mutation carriers ascertained by sampling population complete cancer registries in the United States, Canada and Australia. Using Cox regression weighted to adjust for sampling on family history, we estimated that the country-, age- and sex-specific standardized incidence ratios (SIRs) for monoallelic mutation carriers, compared to the general population, were: 2.04 (95% confidence interval, CI 1.56-2.70; p < 0.001) for CRC, 3.24 (95%CI 2.18-4.98; p < 0.001) for gastric cancer, 3.09 (95%CI 1.07-12.25; p = 0.07) for liver cancer and 2.33 (95%CI 1.18-5.08; p = 0.02) for endometrial cancer. Age-specific cumulative risks to age 70 years, estimated using the SIRs and US population incidences, were: for CRC, 6% (95%CI 5-8%) for men and 4% (95%CI 3-6%) for women; for gastric cancer, 2% (95%CI 1-3%) for men and 0.7% (95%CI 0.5-1%) for women; for liver cancer, 1% (95%CI 0.3-3%) for men and 0.3% (95%CI 0.1-1%) for women and for endometrial cancer, 4% (95%CI 2-8%). There was no evidence of increased risks for cancers of the brain, pancreas, kidney, lung, breast or prostate. Monoallelic MUTYH mutation carriers with a family history of CRC, such as those identified from screening multiple-case CRC families, are at increased risk of colorectal, gastric, endometrial and possibly liver cancers. 相似文献
10.
van Vliet CM Dowty JG van Vliet JL Smith L Mead LJ Macrae FA St John DJ Giles GG Southey MC Jenkins MA Velan GM Hopper JL 《Human mutation》2011,32(2):207-212
Genetic diseases associated with dynamic mutations in microsatellite DNA often display parent-of-origin effects (POEs) in which the risk of disease depends on the sex of the parent from whom the disease allele was inherited. Carriers of germline mutations in mismatch repair (MMR) genes have high risks of colorectal carcinoma (CRC). We investigated whether these risks depend on the parent-of-origin of the mutation. We studied 422 subjects, including 89 MMR gene mutation carriers, from 17 population-based families who were each recruited via a CRC case diagnosed before age 45 years and found to carry a MMR gene mutation. The POE hazard ratio (HR(POE)), defined to be the CRC incidence for carriers with maternally derived mutations divided by the corresponding paternal incidence, was estimated using a novel application of modified segregation analysis. HR(POE) (95% confidence interval) was estimated to be 3.2 (1.1-9.8) for males (P = 0.03) and 0.8 (0.2-2.8) for females (P = 0.5) and the corresponding cumulative risks to age 80 years were 88% (54%-100%) for male carriers with maternally derived mutations and 38-48% for all other carriers. If confirmed by larger studies, these results will have important implications for the etiology of CRC and for the clinical management of MMR gene mutation carriers. 相似文献